SynthesisBMC cancer2020

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.

Kang Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.